Please login to the form below

Not currently logged in
Email:
Password:

Kantar’s Gracie van Kemenade appointed quantitative director at Insight Research Group

Paul O’Meara also joins as regional head of syndicated studies

Gracie van Kemenade has left Kantar Health to join Insight Research Group as quantative director.

She is joined at the market research company by fellow new recruit Paul O'Meara, who has been appointed regional head of syndicated studies.

Van Kemenade was previously global account lead for major pharmaceutical companies at Kantar, and will work across the whole research team in her new role at Insight.

Her main focus will be to work with Insight's existing quantitative research team and apply her experience in the development of new proprietary quantitative research methodologies.

In addition, van Kemenade has experience in market landscape, target product profiling, patient record studies, launch tracking and brand equity research.

Grace van Kemenade - Insight Research GroupPaul O'Meara - Insight Research Group
Gracie van Kemenade and Paul O'Meara

O'Meara was most recently at Ipsos Healthcare where he was head of syndicated studies for the Asia-Pacific region.

Nicola Cowland, joint CEO at Insight Research Group, said of O'Meara and van Kemenade: “Their recruitment is the latest step in bolstering Insight's quantitative research capabilities, developing innovative and valuable new research offerings and affirming our presence as a leading global player in quantitative, qualitative and digital market research in the healthcare sector.”

21st August 2012

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
AMICULUM

AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >300 healthcare communications professionals,...

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...